Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNAseq001

ABSTRACT: scRNAseq001

TISSUE(S): ['tumor']

SUBMITTER: boya zhang

PROVIDER: OEX00027323 | NODE | 2024-02-27

REPOSITORIES: NODE

ACCESS DATA

Json Xml

Similar Datasets

iPSC (Exp 1) - ALS, SMA and Control (unaffected) subject-derived iPSC lines - RNA-seq

Project description:RNA-Seq was carried out on isolated mRNA obtained from induced Pluripotnent Stem Cells (iPSC) cell lines. These lines were derived from ALS, SMA and Control (unaffected) individuals (three of each).

2016-09-01 | LDS-1356 | LINCS

L1000 gene expression profiling assay - DOS small molecule perturbagens

Project description:Transcriptional profiles of U2 OS cell line treated with ~21 thousands of compounds from diversity-oriented-synthesis (DOS) library.

2014-05-30 | LDS-1194 | LINCS

iMN (Exp 2) - ALS, SMA and Control (unaffected) iMN cell lines differentiated from iPS cell lines using a long differentiation protocol - RNA-seq

Project description:Total RNA-Seq was carried out on rRNA depleted RNA obtained from motor neuron lines generated from subject induced pluripotent stem cell (iPSC) lines. The iPSC lines were derived from 4 ALS, 3 SMA and 3 Control (unaffected) individuals, in duplicate.

2017-05-01 | LDS-1398 | LINCS

diMN (Exp 3) - ALS and Control (unaffected) diMN cell lines differentiated from iPS cell lines using a short and direct differeintiation protocol - RNA-seq

Project description:Total RNA-Seq was carried out on rRNA depleted RNA obtained from motor neuron lines generated from subject induced pluripotent stem cell (iPSC) lines. The iPSC lines were derived from 11 ALS and 4 Control (unaffected) individuals, in duplicate.

2017-10-13 | LDS-1499 | LINCS

L1000 Dataset -small molecule, CRISPR perturbagens- LINCS Phase 2 (March 2017)

Project description:Transcriptional profiles of multiple cell and perturbation types: cells are treated with chemical perturbagens and CRISPR reagents. The expression level for 978 representative genes is measured.

2016-03-06 | LDS-1372 | LINCS

3'-DGE mRNA-sequencing transcriptomic dataset for 914 primary human cardiomyocyte cell samples

Project description:Each of 914 cell samples either at the control condition or treated with FDA-approved cancer drugs is sequenced by the single-ended 3'-DGE mRNA-sequencing method with a read length of 46 base pairs, and a total of 914 raw sequence data files in the FASTQ format are generated. These sequence data files are then analyzed by a high-performance computational pipeline and ranked lists of gene signatures and biological processes related to drug-induced cardiotoxicity are generated for each drug. The raw sequence datasets and the analysis results have been carefully controlled for data quality, and they are made publicly available at the Gene Expression Omnibus (GEO) database repository of NIH. As such, this broad drug-stimulated transcriptomi dataset is valuable for the prediction of drug toxicities and their mitigations.

2020-11-09 | LDS-1592 | LINCS

L1000 MCF10A Deep Dive Dataset: treatment with ligands

Project description: Not available

2021-01-20 | LDS-1603 | LINCS

RNA-seq MCF10A Deep Dive Dataset: treatment with ligands

Project description: Not available

2021-01-20 | LDS-1558 | LINCS

L1000 Dataset - small molecule, nucleic acid perturbagens - LINCS Phase 2 (December 2021)

Project description:Transcriptional profiles of multiple cell and perturbation types: cells are treated with chemical and genetic perturbations. The expression level for 978 representative genes is measured.

2021-12-18 | LDS-1611 | LINCS

L1000 Consensus Signatures - CRISPR perturbagens

Project description: Not available

| LDS-1586 | LINCS